Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

A chemical company registered in the U.S. signed a letter urging the Office of the U.S. Trade Representative to exclude from tariffs a product made by its Chinese government-linked parent company — without disclosing that link.

Why it matters: The tariffs remain, but the process illustrates how Chinese-owned companies registered as U.S. entities can lobby the U.S. government to change policies that negatively affect their Chinese parent companies, all without registering as foreign agents.

  • This makes it more difficult to track the potential influence of Chinese corporate- and government-linked interests on U.S. policy.

What's happening: The letter, dated Nov. 13, 2019, and addressed to U.S. Trade Representative Robert Lighthizer, says the U.S. is unable to produce enough PMDI, which is used to make insulation and other household products, to fulfill the needs of U.S. manufacturers.

  • The letter is signed by eight entities, including Wanhua Chemical U.S. Operations LLC and several U.S. roofing and construction companies, as well as an industry group, the Polyisocyanurate Insulation Manufacturers Association (PIMA).
  • In the letter, these groups state they are part of a group called the "Competitive MDI Coalition," which has no website and, unusually for a trade advocacy group, is not registered in federal lobbying databases or in the states where its members are based.
  • "We cannot emphasize enough the adverse impact the tariffs on such a critical input will have on our U.S. manufacturing of downstream products," they wrote.

The big picture: Foreign-owned companies, through their U.S.-registered affiliates, have an avenue to lobby the U.S. government not only by hiring former U.S. elected officials to press their cause, but also through industry and trade groups.

  • Wanhua Chemical is a member of several U.S. industry groups, including the American Chemistry Council and PIMA.
  • Industry groups receive funds from member companies whose contributions are disclosed only to the IRS, not publicly, a phenomenon known as "dark money."
  • The groups are allowed to spend money on donations to super PACS and lobbying.

What they're saying: "Wanhua has been very public with its problems with tariffs," Edward Brzytwa, director for international trade at the American Chemistry Council, a U.S. industry group, told Axios in an interview.

  • "For our purposes, if they’re investing in the U.S., we call them a U.S. chemical manufacturer," he said.
  • Brzytwa later added: "A company needs to manufacture chemical products in the U.S. or sell chemical products in the U.S., among other criteria, to be considered a U.S. chemical manufacturer."

The intrigue: Wanhua Chemical U.S. Operations LLC is owned by Wanhua Chemical Group, a Chinese company that is among the world's largest manufacturers (and exporters) of PMDI.

  • An investment entity owned by a Chinese municipal government is Wanhua Chemical Group's largest shareholder (21.59%), according to the company's 2019 annual report.
  • But Wanhua Chemical U.S. Operations does not disclose this relationship in the letter it signed to Lighthizer, which states it is from "consumers of PMDI."
  • In 2017, Wanhua Chemical Group announced plans to build a $1.25 billion plant to produce MDI in Louisiana, but those plans are now on hold.

Background: Wanhua Chemical U.S. Operations LLC has not registered under the Foreign Agents Registration Act (FARA), nor has Wanhua Chemical Group.

  • But lobbying firms that represent Wanhua have registered their contracts under both the FARA and Senate lobbying databases.
  • In disclosures filed with the Senate database, law firm Alston & Bird wrote, "To the extent that Wanhua Chemical (America) Co., Ltd. realizes any benefit from legislative or executive action, so, too, would its parent company, Wanhua Chemical Group Co. Ltd."
  • AUX Initiatives LLC, a DC-based government affairs consulting firm, filed a FARA registration for its contract with Wanhua Chemical US Operations LLC in August 2018 "out of an abundance of caution."

Calls to phone numbers and emails sent to addresses associated with the U.S.-based affiliates of Wanhua Chemical Group went unanswered.

Editor’s note: This story has been updated with a new quote from Brzytwa, who asked to clarify his earlier comments.

Read the letter.

Go deeper

WarnerMedia-Discovery merger faces questions over Latino programming

Rep. Joaquin Castro (D-Texas). Photo: Jacquelyn Martin/AP Photo/Bloomberg via Getty Images

Rep. Joaquin Castro (D-Texas) and Sen. Elizabeth Warren (D-Mass.) want the Justice Department to review closely a proposed merger of WarnerMedia and Discovery over concerns it could limit programming and opportunities for Latino creators.

Why it matters: Castro has been leading a campaign to pressure media companies to hire more diverse staff and produce more programming with people of color. Media mergers could make that more challenging.

Updated 1 hour ago - Politics & Policy

Omicron dashboard

Illustration: Shoshana Gordon/Axios

  1. Health: Americans shrug off Omicron, Axios-Ipsos poll finds — CDC director says number of U.S. Omicron cases "likely to rise."
  2. Vaccines: Omicron gives a shot to boosters — U.S. announces $400M for global COVID vaccine distribution — Vaccine mandates lose steam in the U.S. while Europe doubles down.
  3. States: Gov. Hochul will order some NY hospitals to halt elective surgeries — Nevada to impose insurance surcharge on unvaccinated state workers.
  4. World: EU drug regulator backs mixing COVID vaccines — Poor global equity likely in COVID pill access — CDC raises travel advisories for France, Portugal to highest level amid COVID surge.
  5. Variant tracker: Where different strains are spreading.

Mark Meadows will stop cooperating with Jan. 6 panel, attorney says

Photo: Chris Kleponis/Polaris/Bloomberg via Getty Images

Former White House chief of staff Mark Meadows will no longer cooperate with the House select committee investigating the Jan. 6 Capitol insurrection, his attorney told Fox News Tuesday.

Why it matters: Meadows, who failed to appear before the panel last month, is believed to have insight into former President Trump's role in efforts to stop the certification of President Biden's election win.